Swiss company Lonza said it is confident that the new U.S. and Swiss plants it’s building to help make Moderna’s COVID-19 vaccine prospect will be ready for commercial production this year. New production lines at Lonza’s site in Portsmouth, New Hampshire, aim to start making vaccine ingredients in November. READ: Couple in COVID-19 vaccine clinical trial share experienceMeanwhile, three lines in a valley in the Swiss alps will begin delivering by December. They plan to supply $300 million vaccine doses annually. READ: Health officials testify science, integrity will guide COVID-19 vaccine processWe’re learning more about how effective the Moderna vaccine may be in older adults.